.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on the general public market.The Eli Lilly-partnered biotech wish to detail on the Nasdaq under the symbolic representation “BIOA,” according to documentations submitted along with the Stocks and Swap Payment. The firm has actually not publicly discussed an expected monetary quantity for the offering.The clinical-stage company touts lead applicant azelaprag, an orally delivered tiny particle slated to get into phase 2 testing in combo along with semaglutide– marketed through Novo Nordisk under trademark name Wegovy for fat burning– in the 1st one-half of next year. Semaglutide is additionally sold as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is made to combine well along with GLP-1 medicines, increasing weight management while maintaining muscular tissue mass. The investigational drug was discovered to become well-tolerated among 265 people throughout eight phase 1 tests, depending on to BioAge.Formerly, BioAge got the assistance of Lilly to operate a trial mixing azelaprag along with the Big Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes as Mounjaro as well as Zepbound for effective weight loss. The partners are actually currently carrying out a phase 2 trial of azelaprag as well as tirzepatide, along with topline results assumed in the third quarter of 2025.The biotech is additionally organizing an insulin sensitivity proof-of-concept test examining azelaprag as a monotherapy in the first one-half of upcoming year to assist potential indicator expansion.
In addition, the business plans to talk to the FDA for authorization in the 2nd fifty percent of 2025 to introduce human testing for an NLRP3 inhibitor targeting metabolic ailments as well as neuroinflammation.BioAge’s expected relocate to everyone market follows a light uptick in considered biotech IPOs coming from Bicara Rehabs and also Zenas Biopharma. Zooming out, the latest IPO garden is actually a “combined photo,” with premium business still debuting on the general public markets, only in minimized amounts, according to PitchBook.